MLi-2
Product Specifications
UNSPSC Description
MLi-2 is an orally active and highly selective LRRK2 inhibitor with an IC50 of 0.76 nM. MLi-2 has the potential for Parkinson’s disease[1].
Target Antigen
LRRK2
Type
Reference compound
Related Pathways
Autophagy
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/MLi-2.html
Purity
99.80
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
C[C@@](C1)([H])O[C@](C)([H])CN1C2=CC(C3=NNC4=CC=C(OC5(C)CC5)C=C43)=NC=N2
Molecular Weight
379.46
References & Citations
[1]Fell MJ, et al. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition. J Pharmacol Exp Ther. 2015 Dec;355(3):397-409.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-100411/MLi-2-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-100411/MLi-2-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
1627091-47-7
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6213808-01 0.1 mL
SAA4 (CSAA, Serum Amyloid A-4 Protein, Constitutively Expressed Serum Amyloid A Protein, C-SAA) (MaxLight 550)
Ask
View Details MBS6213808-02 5x 0.1 mL
SAA4 (CSAA, Serum Amyloid A-4 Protein, Constitutively Expressed Serum Amyloid A Protein, C-SAA) (MaxLight 550)
Ask
View Details 
